HOME > BUSINESS
BUSINESS
- US Pfizer Plans Simultaneous, Global Filing of Five Biosimilars, Eyes Japan Biosimilar Market Entry
November 20, 2013
- Nichi-Iko to Collaborate with Hanoi Pharmaceutical of Vietnam
November 20, 2013
- Takeda, Eisai Earnings Show Signs of Bottoming Out, on Path to Recovery
November 18, 2013
- CMIC Chairman Sorry for Alleged Clinical Data Tampering; Probe Report Due out Late November
November 18, 2013
- PIII Study of Brexpiprazole Starts in US and Europe for Treatment of Agitation in AD: Otsuka Holdings
November 18, 2013
- Sales of Major Japanese Drug Makers Soar 8.1% on Weak Yen, Steady Japan Business
November 15, 2013
- Chugai Puts Off NHI Price Listing for Kadcyla, Agreement Not Reached
November 15, 2013
- Otsuka Holdings Notches Double-Digit Sales Growth in April-September, Weaker Yen Comes as Boon
November 14, 2013
- Chugai Obtains Exclusive Commercialization Rights for Anamorelin in Europe from Helsinn
November 14, 2013
- Kenko.com Sues Government to Affirm Right to Sell Prescription Drugs Online
November 14, 2013
- Generic Market Continues to Grow, Three Generic-Only Makers’ Sales Up 8.8%
November 13, 2013
- Kyowa Kirin Ceases Japan PII Trial on Chronic Kidney Disease Agent
November 13, 2013
- JV of DSP, Japan BCG to Develop New TB Vaccines with NIBIO, US NPO
November 13, 2013
- Antiepileptic Drug Eslicarbazepine Granted US Approval: DSP
November 13, 2013
- Commercial Director Feliciano to Become President of Merck Serono Japan
November 12, 2013
- Eylea Bests Lucentis in Ophthalmic VEGF Inhibitor Market; Santen Ups Sales Outlook for Drug
November 12, 2013
- GLP-1 Dulaglutide “Catalyst of Growth,” SGLT-2 Empagliflozin Will Be Successful Despite Later Launch: Lilly Diabetes President
November 12, 2013
- Ethical Drug Sales Up 5.3% in September: Crecon Report
November 12, 2013
- Eisai to Develop Belviq for Japan Market via Expanded Deal with Arena
November 12, 2013
- NCC, Sanofi Forge Alliance in Anticancer Drug R&D
November 12, 2013
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…